Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

L Falchi; S Leppä; BE Wahlin; M Nijland; JH Christensen; S De Vos; H Holte; KM Linton; A Abbas; LW Wang; M Dinh; B Elliott; D Belada

Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

L Falchi
, S Leppä
, BE Wahlin
, M Nijland
, JH Christensen
, S De Vos
, H Holte
, KM Linton
, A Abbas
, LW Wang
, M Dinh
, B Elliott
, D Belada

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Falchi, L., Leppä, S., Wahlin, BE., Nijland, M., Christensen, JH., De Vos, S., Holte, H., Linton, KM., Abbas, A., Wang, LW., Dinh, M., Elliott, B., & Belada, D. (2022). Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. Journal of Clinical Oncology, 40(16).

@article{935075dcfa924461a48600958db42d91,

title = "Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.",

author = "L Falchi and S Lepp{\"a} and BE Wahlin and M Nijland and JH Christensen and \{De Vos\}, S and H Holte and KM Linton and A Abbas and LW Wang and M Dinh and B Elliott and D Belada",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "16",

}

Falchi, L, Leppä, S, Wahlin, BE, Nijland, M, Christensen, JH, De Vos, S, Holte, H, Linton, KM, Abbas, A, Wang, LW, Dinh, M, Elliott, B & Belada, D 2022, 'Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.', Journal of Clinical Oncology, vol. 40, no. 16.

TY - JOUR

T1 - Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL)

T2 - Update from phase 1/2 trial.

AU - Falchi, L

AU - Leppä, S

AU - Wahlin, BE

AU - Nijland, M

AU - Christensen, JH

AU - De Vos, S

AU - Holte, H

AU - Linton, KM

AU - Abbas, A

AU - Wang, LW

AU - Dinh, M

AU - Elliott, B

AU - Belada, D

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680301985&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

UN SDGs

Other files and links

Cite this